Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB

On March 13, 2023 Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, reported that it will hold a conference call to provide detail and to answer any questions regarding its minority cash holdings at Silicon Valley Bank (SVB) at 8:30 a.m. ET on Monday, March 13th (Press release, Agenus, MAR 13, 2023, View Source [SID1234628549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference Call
Dial-in numbers: (646) 307-1963 (US) or (800) 715-9871 (International)
Conference ID: 9540056.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!